232 related articles for article (PubMed ID: 26583636)
1. Navigating Treatment of Metastatic Castration- Resistant Prostate Cancer: Nursing Perspectives.
dela Rama F; Pratz C
Clin J Oncol Nurs; 2015 Dec; 19(6):723-32. PubMed ID: 26583636
[TBL] [Abstract][Full Text] [Related]
2. Castration-resistant prostate cancer: from new pathophysiology to new treatment.
Sridhar SS; Freedland SJ; Gleave ME; Higano C; Mulders P; Parker C; Sartor O; Saad F
Eur Urol; 2014 Feb; 65(2):289-99. PubMed ID: 23957948
[TBL] [Abstract][Full Text] [Related]
3. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
4. Current therapeutic options in metastatic castration-resistant prostate cancer.
Ingrosso G; Detti B; Scartoni D; Lancia A; Giacomelli I; Baki M; Carta G; Livi L; Santoni R
Semin Oncol; 2018 Oct; 45(5-6):303-315. PubMed ID: 30446166
[TBL] [Abstract][Full Text] [Related]
5. How to approach sequencing therapy in patients with metastatic castration resistant prostate cancer.
Dreicer R
Can J Urol; 2014 Apr; 21(2 Supp 1):93-7. PubMed ID: 24775730
[TBL] [Abstract][Full Text] [Related]
6. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.
Fitzpatrick JM; Bellmunt J; Fizazi K; Heidenreich A; Sternberg CN; Tombal B; Alcaraz A; Bahl A; Bracarda S; Di Lorenzo G; Efstathiou E; Finn SP; Fosså S; Gillessen S; Kellokumpu-Lehtinen PL; Lecouvet FE; Oudard S; de Reijke TM; Robson CN; De Santis M; Seruga B; de Wit R
Eur J Cancer; 2014 Jun; 50(9):1617-27. PubMed ID: 24703899
[TBL] [Abstract][Full Text] [Related]
7. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
[TBL] [Abstract][Full Text] [Related]
8. Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science.
Nussbaum N; George DJ; Abernethy AP; Dolan CM; Oestreicher N; Flanders S; Dorff TB
Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):111-21. PubMed ID: 26832363
[TBL] [Abstract][Full Text] [Related]
9. Improvement in survival and quality of life with new therapeutic agents in metastatic castration-resistant prostate cancer: comparison among the results.
Recine F; Ceresoli GL; Baciarello G; Cerbone L; Calabrò F
Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):400-10. PubMed ID: 26337241
[TBL] [Abstract][Full Text] [Related]
10. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
11. Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence.
Norum J; Nieder C
Pharmacoeconomics; 2017 Dec; 35(12):1223-1236. PubMed ID: 28756597
[TBL] [Abstract][Full Text] [Related]
12. Metastatic castration-resistant prostate cancer: integrating new learnings to optimise treatment outcomes.
Heidenreich A; Porres D; Piper C; Thissen AK; Pfister D
Minerva Urol Nefrol; 2013 Sep; 65(3):171-87. PubMed ID: 23872628
[TBL] [Abstract][Full Text] [Related]
13. Sequencing systemic therapies in metastatic castration-resistant prostate cancer.
Liu JJ; Zhang J
Cancer Control; 2013 Jul; 20(3):181-7. PubMed ID: 23811702
[TBL] [Abstract][Full Text] [Related]
14. Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.
Bahl A; Masson S; Birtle A; Chowdhury S; de Bono J
Cancer Treat Rev; 2014 Feb; 40(1):170-7. PubMed ID: 23958310
[TBL] [Abstract][Full Text] [Related]
15. Sequencing Treatment for Castration-Resistant Prostate Cancer.
Handy CE; Antonarakis ES
Curr Treat Options Oncol; 2016 Dec; 17(12):64. PubMed ID: 27822685
[TBL] [Abstract][Full Text] [Related]
16. Emerging agents for the therapy of advanced prostate cancer.
Hathaway AR; Baker MK; Sonpavde G
Future Oncol; 2015; 11(20):2775-87. PubMed ID: 26367474
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).
Sonpavde G; Wang CG; Galsky MD; Oh WK; Armstrong AJ
BJU Int; 2015 Jul; 116(1):17-29. PubMed ID: 25046451
[TBL] [Abstract][Full Text] [Related]
18. Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer.
Parente P; Parnis F; Gurney H
Asia Pac J Clin Oncol; 2014 Sep; 10(3):205-15. PubMed ID: 24750803
[TBL] [Abstract][Full Text] [Related]
19. Treatment strategies in low-volume metastatic castration-resistant prostate cancer.
Wei XX; Ko EC; Ryan CJ
Curr Opin Urol; 2017 Nov; 27(6):596-603. PubMed ID: 28786849
[TBL] [Abstract][Full Text] [Related]
20. Therapy Update for Metastatic Castration-Resistant Prostate Cancer.
Dinh JA; Baker D; Chahal M
Consult Pharm; 2016; 31(10):581-592. PubMed ID: 27725068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
